Last updated: March 28, 2026
What Is NDC 23155-0796?
NDC 23155-0796 refers to a specific pharmaceutical product registered in the National Drug Code database. Based on available data, this NDC corresponds to Sunitinib malate, marketed under the brand name Sutent, used primarily in cancer treatment.
Market Size and Population Demographics
Global Market
The global oncology drug market was valued at approximately USD 175 billion in 2022. Sunitinib accounts for a significant share within targeted therapies for renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST).
U.S. Market
In the United States, Sunitinib generated revenue of USD 1.6 billion in 2022, representing about 9% of the targeted oncology segment. The patient population for RCC and metastatic GIST is estimated at 70,000 annually.
Market Drivers
- Increased incidence of RCC and GIST
- Expansion of combination therapies
- Advances in biomarker-driven treatment approaches
- Patent expiry and biosimilar entry timeline
Competitive Landscape
Key Competitors
| Drug Name |
Indication |
Market Share (2022) |
Price Range (per 28-day supply) |
| Sutent (Sunitinib) |
RCC, GIST |
65% |
USD 9,500 – 12,000 |
| Pazopanib |
RCC |
20% |
USD 7,000 – 9,500 |
| Cabozantinib |
RCC, GIST, thyroid cancer |
10% |
USD 12,000 – 15,000 |
| Other |
Various rare indications |
5% |
Varies |
Patent and Biosimilar Landscape
- The patent for Sutent expired in May 2022 in the U.S.
- Biosimilars are under development, with potential launches as early as 2024.
- Price competition from biosimilars could reduce branded drug prices by 20-30% over the next two years.
Price Projections (2023-2027)
Current Pricing
- Average retail price: USD 10,000 per 28-day supply.
- Insurance coverage varies; copayments range from USD 30 to USD 200 per month for insured patients.
Short-Term (2023-2024)
- Prices are expected to decline due to biosimilar competition.
- Projected price decline: 15-20% over 12-18 months.
- Biosimilar entry could reduce the average price to USD 8,000 – USD 8,500.
Medium-Term (2024-2026)
- Price stabilization around USD 7,500 – USD 8,000 per 28-day supply.
- Revenue impact primarily driven by volume increases, partially offsetting price declines.
- Market penetration of biosimilars could expand accessibility, especially in Europe and emerging markets.
Long-Term (2027 and beyond)
- Total market growth driven by increased diagnosis rates, expanded indications, and biosimilar adoption.
- Prices could stabilize further, with potential reductions of 5-10% driven by payer negotiations and cost-containment strategies.
- Entry of next-generation targeted therapies could reduce demand for Sunitinib, influencing pricing strategies.
Regulatory and Policy Impact
- The U.S. FDA approval of biosimilars will influence pricing broadly.
- Price negotiations under Medicare and other payers could further pressure prices downward.
- International reference pricing policies may align global prices with U.S. trends.
Revenue Outlook
| Year |
Estimated Global Revenue |
Growth Rate |
Key Factors |
| 2023 |
USD 1.6 billion |
N/A |
Patent expiry, biosimilar competition, price decline |
| 2024 |
USD 1.4 billion |
-8% |
Biosimilar launches, volume growth |
| 2025 |
USD 1.3 billion |
-7% |
Market saturation, price stabilization |
| 2026 |
USD 1.2 billion |
-5% |
Increased biosimilar adoption, new indications |
Key Takeaways
- NDC 23155-0796 (Sunitinib) is a leading targeted therapy for certain cancers.
- The market is experiencing price pressure due to patent expiration and biosimilar development.
- Short-term prices are projected to decline 15-20%; long-term stabilization around USD 7,500-8,000.
- Revenue is declining slightly but remains substantial due to high prevalence and expanding indications.
- Payers and policymakers will continue to influence future pricing through negotiations and regulation.
FAQs
1. How will biosimilar competition impact the price of Sunitinib? Biosimilar entry is expected to reduce prices by 20-30% over two years, affecting both branded and generic markets.
2. What are the main indications for NDC 23155-0796? Primarily renal cell carcinoma and gastrointestinal stromal tumors.
3. Is there potential for new indications to influence its market? Yes. Expansion into additional tumor types and combination therapies can sustain or grow revenue despite price reductions.
4. How does geographic market regulation affect pricing? Countries with strict price controls, like many European nations, tend to have lower prices than the U.S., influencing global price trends.
5. When could the U.S. patent for Sutent expire? The patent expired in May 2022; biosimilars should begin entering the market shortly thereafter.
References
- IQVIA Institute for Human Data Science. (2023). The Global Oncology Market Report.
- U.S. Food and Drug Administration. (2022). Biologics License Application Approvals.
- EvaluatePharma. (2023). Oncology Market Outlook.
- Generic Pharmaceutical Association. (2022). Biosimilar Market Development Report.
- Medicare.gov. (2023). Drug Price Negotiation Policies and Impacts.
